NCT07136012
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Recruiting
PHASE3Ages 50+InterventionalTreatmentAmgen
~11,000 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:OlpasiranPlacebo
At a glance
Recruiting sites
240 of 252 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to CHD Death, Myocardial Infarction, or Urgent Coronary Revascularization, Whichever Occurs First
Measured over Up to approximately 6.2 years
Conditions
Where it's being run
252 sites across 48 statesTexas25
Florida21
California14
Ontario12
New York11
New Jersey10
Virginia10
Maryland9
Study leadership
- MD · STUDY_DIRECTOR · Amgen
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age ≥50 years
Lp(a)≥ 200 nmol/L during screening
Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis
Exclusion
Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia)
Prior or planned arterial revascularization
History of major bleeding disorder
What this trial measures
- Time to CHD Death, Myocardial Infarction, or Urgent Coronary Revascularization, Whichever Occurs FirstUp to approximately 6.2 years